Open AccessThe cognitive effects of anticholinergic drugs on apolipoprotein ε4 carriers and noncarriers in the Wisconsin Registry for Alzheimer’s Prevention study.
Author(s) -
Brian G. Collin,
Dheeraj Raju,
Steven Katsikas
Publication year - 2021
Publication title -
neuropsychology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 130
eISSN - 1931-1559
pISSN - 0894-4105
DOI - 10.1037/neu0000713
Subject(s) - anticholinergic , psychomotor learning , psychology , cognition , memory clinic , dementia , cognitive decline , effects of sleep deprivation on cognitive performance , psychiatry , medicine , clinical psychology , cognitive impairment , disease
The purpose of the study was to test the hypothesis that anticholinergic drug exposure is associated with cognitive decline in the Wisconsin Registry for Alzheimer's Prevention (WRAP) study. Secondary aims were to assess if the effects of anticholinergic drugs on different domains of cognitive functioning varied for the entire sample and by apolipoprotein ε4 status.